Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Stock Forecast
Show ratings and price targets of :
Alert
Its only available to paid users.
USD 11.33
(+51.52%)
Based on the Amneal Pharmaceuticals, Inc. Class A Common Stock stock forecast from 3 analysts, the average analyst target price for Amneal Pharmaceuticals, Inc. Class A Common Stock is USD 11.33 over the next 12 months. Amneal Pharmaceuticals, Inc. Class A Common Stock’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Amneal Pharmaceuticals, Inc. Class A Common Stock is Neutral, which is based on 6 positive signals and 6 negative signals. At the last closing, Amneal Pharmaceuticals, Inc. Class A Common Stock’s stock price was USD 7.48. Amneal Pharmaceuticals, Inc. Class A Common Stock’s stock price has changed by +1.63% over the past week, -9.50% over the past month and +27.43% over the last year.
No recent analyst target price found for Amneal Pharmaceuticals, Inc. Class A Common Stock
No recent average analyst rating found for Amneal Pharmaceuticals, Inc. Class A Common Stock
Company Overview Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey. Read Less
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Speci...Read More
Frequently Asked Questions About Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Stock
Based on ratings from 3 analysts Amneal Pharmaceuticals, Inc. Class A Common Stock's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on AMRX's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for AMRX is USD 11.33 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 11.
AMRX stock's Price/Earning ratio is 89.83.
Our analysis grades AMRX stock's Price / Earning ratio at F. This means that AMRX stock's Price/Earning ratio is above 87% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NYE exchange.
Based on this AMRX may be a overvalued for its sector.
The last closing price of AMRX's stock was USD 7.48.
The most recent market capitalization for AMRX is USD 3.25B.
Based on targets from 3 analysts, the average taret price for AMRX is projected at USD 11.33 over the next 12 months.
This means that AMRX's stock price may go up by +51.52% over the next 12 months.
We can't find any ETFs which contains Amneal Pharmaceuticals, Inc. Class A Common Stock's stock.
As per our most recent records Amneal Pharmaceuticals, Inc. Class A Common Stock has 8,300 Employees.
Amneal Pharmaceuticals, Inc. Class A Common Stock's registered address is 400 Crossing Boulevard, Bridgewater, NJ, United States, 08807.
You can get more information about it from Amneal Pharmaceuticals, Inc. Class A Common Stock's website at https://www.amneal.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Stock
Based on ratings from 3 analysts Amneal Pharmaceuticals, Inc. Class A Common Stock's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on AMRX's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for AMRX is USD 11.33 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 11.
AMRX stock's Price/Earning ratio is 89.83.
Our analysis grades AMRX stock's Price / Earning ratio at F. This means that AMRX stock's Price/Earning ratio is above 87% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NYE exchange.
Based on this AMRX may be a overvalued for its sector.
The last closing price of AMRX's stock was USD 7.48.
The most recent market capitalization for AMRX is USD 3.25B.
Based on targets from 3 analysts, the average taret price for AMRX is projected at USD 11.33 over the next 12 months.
This means that AMRX's stock price may go up by +51.52% over the next 12 months.
We can't find any ETFs which contains Amneal Pharmaceuticals, Inc. Class A Common Stock's stock.
As per our most recent records Amneal Pharmaceuticals, Inc. Class A Common Stock has 8,300 Employees.
Amneal Pharmaceuticals, Inc. Class A Common Stock's registered address is 400 Crossing Boulevard, Bridgewater, NJ, United States, 08807.
You can get more information about it from Amneal Pharmaceuticals, Inc. Class A Common Stock's website at https://www.amneal.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AMRX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
